Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Sponsor: Xijing Hospital
Summary
The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.
Official title: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease: a Single-center, Placebo-controlled, Exploratory, Phase 2, Pilot Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2024-10-16
Completion Date
2027-03-01
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
Mepolizumab low dose group
Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
Mepolizumab middle dose group
Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
Mepolizumab high dose group
Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
Saline
Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
Locations (1)
Ling Tao
Xi'an, Shannxi, China